EPO Biosimilars - The Future of Erythropoietin Market

Published: Aug, 2016 | Pages: 45 | Publisher: RNCOS
Industry: Healthcare | Report Format: Electronic (PDF)

Erythropoietin is a hormone produced by healthy kidneys. This hormone prompts the bone marrow to make the red blood cells, which then carry oxygen throughout the body. Erythropoietin is used to treat anemia resulting from kidney failure or cancer treatment. It is considered to be an alternative to blood transfusions. Over the last few years, the global erythropoietin industry has been showing a sluggish growth due to patent expiry of biologic drugs. However, the biosimilar versions of these drugs are expected to witness precipitous growth owing to their low cost.

As per RNCOS report "EPO Biosimilars - The Future of Erythropoietin Market", the global erythropoietin market is anticipated to reach an approximate value of US$ 7 Billion by 2020. This report provides a detailed analysis of the current and future market scenario of the global erythropoietin market. The report highlights biosimilar erythropoietin at various stages of clinical development. In addition, the report provides insight about the major drivers and challenges, along with the latest trends and developments impacting the industry growth.

The global erythropoietin market has been segmented into biologic and biosimilar erythropoietin markets. The report also highlights the various biologic and biosimilar erythropoietin drugs currently available in the market. Furthermore, the global erythropoietin market has also been segmented on the basis of their applications. Based on geography, the report divides the market into the US, Europe, and Asia-Pacific.

The last section of the report discusses about the prominent players in global erythropoietin market. Market share analysis of these players is also provided in the report. A brief business overview and financial information about each of these players has been provided along with their product portfolios. The recent development of every player has also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global erythropoietin market.

 Table of Contents
1. Analyst View
2. Research Methodology
3. Industry Trends and Drivers
     3.1 Biosimilars Opens Array of Opportunity for Market Growth
     3.2 Growing Geriatric Population
     3.3 Increasing Incidences of Chronic Diseases
     3.4 Ability to Curb Healthcare Cost
4. Industry Challenges
     4.1 High Prices
     4.2 Stringent Regulatory Processes
     4.3 Threat from Substitutes
5. Global Protein Therapeutics Market
     5.1 Protein Therapeutics Market Vs Pharmaceutical Market
     5.2 Current and Future Market Analysis for 2022
     5.3 Market Segmentation
6. Erythropoietin Market - Introduction
7. Global Erythropoietin Market Outlook to 2022
8. Market Segmentation
     8.1 By Type
            8.1.1 Biologic
            8.1.2 Biosimilar
     8.2 By Application
     8.3 By Drug
9. Global Erythropoietin Market by Geography
     9.1.1 US
     9.1.2 Europe
     9.1.3 Asia-Pacific
10. Pipeline Analysis of Erythropoietin
11. Competitive Landscape
       11.1 Share of Major Players
       11.2 Key Players Analysis
                11.2.1 Amgen Inc.
                11.2.2 Johnson & Johnson
                11.2.3 Roche Group
                11.2.4 Pfizer Inc.
                11.2.5 Novartis

List of Tables:

Table 8-1: Global - Biologic Erythropoietin Drugs and Their Sales
Table 10-1: Global - Erythropoietin Product Pipeline
Table 11-1: Amgen Inc. - Total Company Revenue (Billion US$), 2013, 2014 & 2015
Table 11-2: Amgen Inc. - Commercialized Erythropoietin Products
Table 11-3: Amgen Inc. - Erythropoietin Product Sales (Billion US$), 2013, 2014 & 2015
Table 11-4: Johnson & Johnson - Total Company Sales (Billion US$), 2013, 2014 & 2015
Table 11-5: Johnson & Johnson - Commercialized Erythropoietin Products
Table 11-6: Johnson & Johnson - Erythropoietin Product Sales (Billion US$), 2013, 2014 & 2015
Table 11-7: Roche - Total Company Revenue (Billion US$), 2013, 2014 & 2015
Table 11-8: Roche - Commercialized Erythropoietin Products
Table 11-9: Roche - Erythropoietin Product Sales (Billion US$), 2013, 2014 & 2015
Table 11-10: Pfizer Inc. - Total Company Revenue (Billion US$), 2013, 2014 & 2015
Table 11-11: Pfizer Inc. - Commercialized Erythropoietin Products
Table 11-12: Novartis - Total Company Sales (Billion US$), 2013, 2014 & 2015
Table 11-13: Novartis - Commercialized Erythropoietin Products